Trial · NCT01171690
Teriparatide for Postsurgical Hypoparathyroidism
NCT01171690, Phase 2, Terminated, Mayo Clinic; results first posted 2014-12-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Teriparatide for Postsurgical Hypoparathyroidism. Trials, record NCT01171690. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01171690
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Teriparatide for Postsurgical Hypoparathyroidism
- NCT number
- NCT01171690
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Hypoparathyroidism Post-surgical
- Interventions
- Teriparatide
- First posted
- 2010-07-28
- Last updated
- 2014-12-22
- Results first posted
- 2014-12-22
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hospital Length of Stay | Approximately 7 days after surgery | Hospital length of stay from initiation of therapy with calcium and calcitriol to "ready to discharge" from a calcium perspective (calcium level \> 7.5 mg/dL and increasing x 2 over 12 hours in an asymptomatic patient with stable therapy and no need for intravenous (IV) calcium in last 24 hours). |
| Secondary | Safety Analysis | Approximately 90 days after surgery | Arms were compared for total number of adverse events, including severe and serious adverse events. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Hospital Length of Stay | Approximately 7 days after surgery | days | MEAN | |
| SECONDARY | Safety Analysis | Approximately 90 days after surgery | events | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Hospital Length of Stay | Teriparatide | 1.1 | Standard Deviation 0.4 | days | |
| Hospital Length of Stay | Control | 2.4 | Standard Deviation 1.1 | days | |
| Safety Analysis | Teriparatide | 0 | events | ||
| Safety Analysis | Control | 0 | events |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Teriparatide | 5 | |
| Overall Study | STARTED | Control | 5 | |
| Overall Study | COMPLETED | Teriparatide | 5 | |
| Overall Study | COMPLETED | Control | 5 | |
| Overall Study | NOT COMPLETED | Teriparatide | 0 | |
| Overall Study | NOT COMPLETED | Control | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Teriparatide | ||
| Total, all-cause mortality | Control | ||
| Total, other adverse events | Teriparatide | 0 | 5 |
| Total, other adverse events | Control | 0 | 5 |
| Total, serious adverse events | Teriparatide | 0 | 5 |
| Total, serious adverse events | Control | 0 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Teriparatide vs Control: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01171690
GET https://conductscience.org/api/trials/v1/NCT01171690/registered